Conference item icon

Conference item

A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjx180.486

Authors


Expand authors...
Publisher:
Oxford University Press Publisher's website
Volume:
12
Issue:
supplement_1
Pages:
S285–S286
Publication date:
2018-01-16
Acceptance date:
2018-01-16
DOI:
EISSN:
1876-4479
ISSN:
1873-9946
Pubs id:
pubs:844217
URN:
uri:389cc7fa-f070-411b-ac12-938f49894513
UUID:
uuid:389cc7fa-f070-411b-ac12-938f49894513
Local pid:
pubs:844217

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP